📈 Jumpstart Signal Watchlist — September 08, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $12.88 is 9% below 3yr high $14.14 · ⏳ SMA200 $6.63 (current price $12.88 is above) · 💰 Market Cap $727M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (16.0%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Paysign Targets $117M Revenue as Patient-Affordability Business Surges — MarketBeat.
🤖 Paysign expects 2026 revenue of $114 million-$117 million and adjusted EBITDA of $35 million-$38 million. Patient-affordability revenue grew more than 85% in the first half, supporting a favorable growth outlook.
✅ Paysign: Growth In Both Segments, But Guidance Implies Lower H2 — Seeking Alpha.
🤖 The article highlights 48.1% year-over-year second-quarter revenue growth to $28.3 million, an earnings beat, and raised 2026 guidance. The potential for lower second-half earnings tempers the otherwise positive assessment.
❌ Paysign (NASDAQ:PAYS) Stock Rating Lowered by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen lowered Paysign from “strong-buy” to “buy,” representing a modest downgrade in analyst sentiment. The broader analyst consensus remained “Buy,” limiting the negative impact.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 Current $22.86 is 2% below 3yr high $23.38 · ⏳ SMA200 $15.79 (current price $22.86 is above) · 💰 Market Cap $626M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 150% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.46 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Ooma (OOMA) Rides A Phone Line Extinction Into Faster Growth — Yahoo Finance.
🤖 The article presents Ooma’s transition away from traditional phone lines as supporting faster growth, making it favorable for the stock.
✅ Ooma Inc earnings beat by $0.02, revenue topped estimates — Investing.com.
🤖 Ooma reported second-quarter EPS of $0.35 versus the $0.33 analyst estimate, while revenue of $83.2 million exceeded the $81.72 million consensus. The earnings and revenue beats are positive catalysts.
✅ What is Benchmark's Forecast for Ooma FY2027 Earnings? — MarketBeat.
🤖 Benchmark raised its FY2027 EPS forecast for Ooma from $0.83 to $0.89 while maintaining a Buy rating, indicating improved analyst expectations.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $57.67 is 2% below 3yr high $59.13 · ⏳ SMA200 $47.57 (current price $57.67 is above) · 💰 Market Cap $14.4B
- EXEL passed all filters and shows favorable conditions.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (mixed coverage).
✅ Exelixis (NASDAQ:EXEL) Stock Rating Upgraded by Zacks Research — MarketBeat.
🤖 Zacks Research upgraded Exelixis from “strong sell” to “hold.” Although the broader consensus remained “hold,” the upgrade represented a more favorable analyst view and shares were reported near a 52-week high.
✅ Exelixis Announces Update on Patent Litigation Trial — Business Wire via Yahoo Finance.
🤖 The Federal Circuit upheld the validity of three patents covering cabozantinib and dismissed another patent-related appeal as moot. The ruling preserves CABOMETYX market exclusivity, with the earliest potential generic launch pushed to January 15, 2030, subject to further proceedings.
❌ EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis — PR Newswire.
🤖 The announcement concerned a shareholder investigation into potentially misleading company statements after Exelixis lowered and narrowed its 2026 revenue guidance because of a slower-than-expected neuroendocrine-tumor ramp. The reduced outlook and potential securities claims create negative sentiment for the stock.
❌ Exelixis (EXEL) Q2 2026 Earnings Call Transcript — The Motley Fool.
🤖 The earnings call transcript reported $628.7 million in revenue, up 10.6% year over year, and EPS above consensus, but also documented a reduction in full-year 2026 revenue guidance to $2.50 billion–$2.55 billion. The guidance cut, attributed to a slower neuroendocrine-tumor sales ramp, was a negative catalyst despite the EPS beat.
⚪️ Exelixis (NASDAQ:EXEL) Sets New 12-Month High - Still a Buy? — MarketBeat.
🤖 Exelixis reached a new 52-week high and exceeded quarterly EPS expectations, but revenue missed consensus estimates and the average analyst price target remained below the share price. These offsetting factors make the overall implication mixed.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 Current $56.03 is 6% below 3yr high $59.82 · ⏳ SMA200 $33.18 (current price $56.03 is above) · 💰 Market Cap $74.4B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 405% (>20%); Revenue growth 34% (>15%); Low LT D/E 0.82 (<1.0); PEG ratio 0.07 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.4%)
- 🔔 Strong above EMA50 (11.4%)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ HPE CEO on AI boom: 'Customers are buying everything' — Yahoo Finance.
🤖 HPE reported fiscal third-quarter revenue of $12.21 billion, up 34% year over year, and adjusted EPS of $1.11. Management also raised its fiscal 2027 revenue-growth outlook to 13%–17%, reflecting strong AI demand.
✅ HPE Raises 2026 and 2027 Guidance, Expands Oracle Networking ... — Yahoo Finance.
🤖 HPE exceeded quarterly revenue and earnings expectations and raised guidance for both 2026 and 2027. Its expanded Oracle collaboration and Juniper networking services agreement add strategic support, although supply constraints caused an initial share-price decline.
✅ Hewlett Packard Enterprise Q3 Earnings Call Highlights — Yahoo Finance.
🤖 HPE delivered record third-quarter revenue, EPS, and free cash flow, with orders up 42% and a record backlog. The company raised its outlook, though component shortages may limit revenue conversion through fiscal 2027.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: Amphenol Corporation designs and manufactures electrical, electronic, and fiber-optic connectors, sensors, and interconnect systems. Its products are used in markets including aerospace, defense, automotive, information technology, telecommunications, industrial equipment, and medical devices.
- 🎯 Current $81.76 is 6% below 3yr high $86.49 · ⏳ SMA200 $71.43 (current price $81.76 is above) · 💰 Market Cap $100.3B
- APH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 59% (>20%); Revenue growth 55% (>15%); ROE 33% (>15%); Low LT D/E 0.21 (<1.0).
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Amphenol (APH) Upgraded to Strong Buy: Here's Why — Yahoo Finance.
🤖 Amphenol received a Zacks Rank #1 Strong Buy upgrade after upward revisions to earnings estimates. The consensus estimate for 2026 earnings increased 11.8% over the prior three months, supporting a favorable outlook.
✅ Dear Amphenol Stock Fans, Mark Your Calendars for September 2 — Yahoo Finance.
🤖 The article discusses the completed two-for-one stock split and notes that analysts remained bullish, with a consensus Strong Buy rating and substantial upside to the average price target. The split itself does not change intrinsic value but may improve accessibility and investor interest.
❌ Amphenol Corp. Cl A stock underperforms Tuesday when compared to competitors — MarketWatch.
🤖 Amphenol shares fell 1.23% on September 8, underperforming several competitors during a broadly weak market session. The decline snapped a two-day winning streak, though it was largely presented as market-related rather than company-specific.
🍭 Bonus (B): 0/10 — Electronic Connectors

🏢 What they do: ScanSource is a technology distributor that connects hardware, software, connectivity, and cloud solutions to channel partners and businesses. Its products and services include point-of-sale systems, barcode and data-capture equipment, networking, communications, physical security, payments, and related value-added services.
- 🎯 Current $57.69 is 2% below 3yr high $58.89 · ⏳ SMA200 $44.15 (current price $57.69 is above) · 💰 Market Cap $1.2B
- SCSC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 40% (>20%); Revenue growth 17% (>15%); Low LT D/E 0.38 (<1.0).
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ ScanSource (NASDAQ:SCSC) Upgraded by Wall Street Zen to Strong-Buy Rating — MarketBeat.
🤖 Wall Street Zen raised ScanSource to a strong-buy rating, which is a favorable analyst-action catalyst for the stock. The article also notes the broader analyst consensus remains mixed, but the upgrade itself is positive.
✅ ScanSource (NASDAQ:SCSC) Upgraded at Zacks Research — MarketBeat.
🤖 Zacks Research upgraded ScanSource from hold to strong-buy, a constructive analyst revision that can support the shares. The article also references other recent analyst changes, reinforcing that the stock has become more favorably viewed by some firms.
⚪️ ScanSource (NASDAQ:SCSC) Downgraded by Northcoast Research to Neutral — MarketBeat.
🤖 Northcoast Research downgraded ScanSource from buy to neutral, which is a mixed signal but not clearly bearish. Because analyst downgrades can pressure sentiment, the article is neutral overall rather than positive.
🍭 Bonus (B): 0/10 — Computers & Software - Wholesale